Verrica Pharmaceuticals
VRCA
49 hedge funds and large institutions have $115M invested in Verrica Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 9 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
2% more capital invested
Capital invested by funds: $112M → $115M (+$2.31M)
0.29% less ownership
Funds ownership: 3.63% → 3.33% (-0.29%)
8% less funds holding
Funds holding: 53 → 49 (-4)
34% less call options, than puts
Call options by funds: $329K | Put options by funds: $502K
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$494K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$281K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$227K |
| 4 |
State Street
Boston,
Massachusetts
|
+$149K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.4M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.02M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.05M |
| 4 |
Morgan Stanley
New York
|
-$869K |
| 5 |
BlackRock
New York
|
-$646K |
VRCA Hedge Fund Activity: Q3 2021 in Review
49 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2021, worth a combined $115M — up 2.1% from $112M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VRCA and 5 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 17 added.
The largest buyer was Susquehanna International Group, adding an estimated $494K. The largest seller was Millennium Management, cutting an estimated $3.4M.
- 49 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2021, down from 53 in Q2 2021.
- Funds reported $115M of Verrica Pharmaceuticals stock for Q3 2021, up 2.1% quarter-over-quarter.
- 5 funds opened new Verrica Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of -4 holders.
- The largest Verrica Pharmaceuticals buyer in Q3 2021 was Susquehanna International Group, an estimated $494K added.
- The largest Verrica Pharmaceuticals seller in Q3 2021 was Millennium Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q3 2021.